BioCentury
ARTICLE | Clinical News

Tenofovir exalidex: Interim Ph IIa data

April 28, 2017 5:57 PM UTC

Interim data from 12 treatment-naïve patients with HBV infection in an open-label, Thai Phase IIa trial showed that once-daily 100 mg oral tenofovir exalidex led to a lower mean HBV viral load after 2...

BCIQ Target Profiles

Viral DNA polymerase